Sensible Biotechnologies is developing world's first cell-based platform to unlock the next generation of mRNA medicines.
Sensible Biotechnologies has raised $4.2M in total funding. The most recent round was Pre-Seed. The last funding was announced in April 2023.
Sensible Biotechnologies's investors include Y Combinator, BlueYard Capital, Civilization Ventures, ZAKA VC, Possible Ventures.
Sensible Biotechnologies is headquartered in Cambridge, United States.
Sensible Biotechnologies is developing world's first cell-based platform to unlock the next generation of mRNA medicines.
Sensible Biotechnologies is at the Pre-Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Sensible Biotechnologies — Funding & Investors." VCBacked, April 6, 2023, https://www.vcbacked.co/company/sensible-biotechnologies. Accessed July 19, 2026.
VCBacked. (2023). Sensible Biotechnologies — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/sensible-biotechnologies
{{cite web |title=Sensible Biotechnologies — Funding & Investors |url=https://www.vcbacked.co/company/sensible-biotechnologies |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated